Frank G. Pilkiewicz
Plus aucun poste en cours
Profil
Frank G.
Pilkiewicz was the founder who founded Transave, Inc. in 1999, where he held the title of President & Chief Executive Officer until 2006.
He also held former positions as President & Chief Executive Officer at CellXplore, Inc. from 2008 to 2010, Chairman, President & Chief Executive Officer at Adgero Biopharmaceuticals Holdings, Inc., Director & Chief Scientific Officer at Oncotherapeutics, Inc. from 1992 to 1995, and Vice President-Research & Development at The Liposome Co., Inc. from 1986 to 1992.
Dr. Pilkiewicz's education history includes a graduate and doctorate degree from Rutgers State University of New Jersey and an undergraduate degree from Saint Peter's University.
Anciens postes connus de Frank G. Pilkiewicz
| Sociétés | Poste | Fin |
|---|---|---|
CellXplore, Inc.
 CellXplore, Inc. BiotechnologyHealth Technology CellXplore, Inc. operates as a biotechnology company which engages in the development of biomarker-based in vitro diagnostic assays. The firm commercializes groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions. The company was founded by Kiran Madura on September 24, 2007 and is headquartered in New Brunswick, NJ. | Directeur Général | 01/01/2010 |
Transave, Inc.
 Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Directeur Général | 01/01/2006 |
Oncotherapeutics, Inc.
 Oncotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Oncotherapeutics, Inc. develops and manufactures therapeutic cancer drugs and biomarkers. The firm is a service contract research organization (CRO) with a unique focus on the oncology therapeutic area. Its program encompasses laboratory research, protocol concept, design and development, clinical trial management, monitoring, data management, biostatistics, safety review, clinical and database auditing, medical monitoring, and medical writing. Oncotherapeutics was founded in 1988 and is headquartered in West Hollywood, CA. | Directeur Technique/Scientifique/R&D | 01/01/1995 |
The Liposome Co., Inc.
 The Liposome Co., Inc. Pharmaceuticals: MajorHealth Technology The Liposome Co., Inc. is a biopharmaceutical company engaged in the discovery, development, manufacturing and marketing of proprietary lipid- and liposome-based pharmaceuticals, primarily for the treatment of cancer and other related life-threatening illnesses. | Corporate Officer/Principal | 01/01/1992 |
Adgero Biopharmaceuticals Holdings, Inc.
 Adgero Biopharmaceuticals Holdings, Inc. Medical SpecialtiesHealth Technology Adgero Biopharmaceuticals Holdings, Inc. a biopharmaceutical company. It focuses on the development of photodynamic therapy for the treatment of rare, unmet medical needs, with particular emphasis on orphan cancer indications. The firm offers candidate, REM-001 therapy, consists of three parts, a laser light source, a light delivery device and the drug REM-001. The company is headquartered inv Princeton, NJ. | Directeur Général | - |
Formation de Frank G. Pilkiewicz
| Rutgers State University of New Jersey | Doctorate Degree |
| Saint Peter's University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
The Liposome Co., Inc.
The Liposome Co., Inc. Pharmaceuticals: MajorHealth Technology The Liposome Co., Inc. is a biopharmaceutical company engaged in the discovery, development, manufacturing and marketing of proprietary lipid- and liposome-based pharmaceuticals, primarily for the treatment of cancer and other related life-threatening illnesses. | Health Technology |
Oncotherapeutics, Inc.
Oncotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Oncotherapeutics, Inc. develops and manufactures therapeutic cancer drugs and biomarkers. The firm is a service contract research organization (CRO) with a unique focus on the oncology therapeutic area. Its program encompasses laboratory research, protocol concept, design and development, clinical trial management, monitoring, data management, biostatistics, safety review, clinical and database auditing, medical monitoring, and medical writing. Oncotherapeutics was founded in 1988 and is headquartered in West Hollywood, CA. | Commercial Services |
Transave, Inc.
Transave, Inc. Pharmaceuticals: MajorHealth Technology Transave, Inc. is a biopharmaceutical company focused on developing innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases such as pulmonary infections in cystic fibrosis patients and cancers affecting the lung. They are committed to significantly improving the quality of life and healthcare of patients suffering from these life-threatening diseases. Its operating principles are centered on teamwork, openness, mutual respect, diversity of opinion, trust, accountability and innovative science. They are developing products based on Transave's proprietary liposomal technology designed specifically for lung delivery. Its focus is on reformulating off-patent, established drugs into unique liposomal technology - based inhaled pharmaceuticals for the localized, site-specific treatment of serious lung diseases. Transave's proprietary liposomal technology allows for the sustained release of a drug in the lung's microenvironment. By remaining in the lungs for a prolonged period and potentially minimizing systemic exposure, Transave's liposomal technology offers the potential for changing the product profile, improving delivery of the compound to the lung and enhancing the therapeutic index of established pharmaceuticals. | Health Technology |
CellXplore, Inc.
CellXplore, Inc. BiotechnologyHealth Technology CellXplore, Inc. operates as a biotechnology company which engages in the development of biomarker-based in vitro diagnostic assays. The firm commercializes groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions. The company was founded by Kiran Madura on September 24, 2007 and is headquartered in New Brunswick, NJ. | Health Technology |
Adgero Biopharmaceuticals Holdings, Inc.
Adgero Biopharmaceuticals Holdings, Inc. Medical SpecialtiesHealth Technology Adgero Biopharmaceuticals Holdings, Inc. a biopharmaceutical company. It focuses on the development of photodynamic therapy for the treatment of rare, unmet medical needs, with particular emphasis on orphan cancer indications. The firm offers candidate, REM-001 therapy, consists of three parts, a laser light source, a light delivery device and the drug REM-001. The company is headquartered inv Princeton, NJ. | Health Technology |